ReviewFrontiers in microbiology2022
Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective.
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Efficacy of novel SARS-CoV2 vaccines in preventing SARS- CoV- 2 infection: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study.Scientific reports · 2024Trial
- Dynamics of an SVEIR transmission model with protection awareness and two strains.Infectious Disease Modelling · 2025Article
- Uptake and hesitancy of the second booster dose of COVID-19 vaccine among the general population in China after the surge period of the COVID-19 pandemic: a large-scale national study.BMC public health · 2025Article
- New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.Enfermedades infecciosas y microbiologia clinica · 2025Review
- T cell receptor usage and epitope specificity amongst CD8Frontiers in immunology · 2025Article
- Effect of Homologous and Heterologous Booster in COVID-19 Vaccination.Pharmaceuticals (Basel, Switzerland) · 2024Article
- AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors.Journal of chemical information and modeling · 2024Article
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine Booster Doses in Kidney Transplant Recipients: Results of a 12-mo Follow-up From a Prospective Observational Study.Transplantation direct · 2024Article
- Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges.NPJ vaccines · 2024Article
- Alterations of SARS-CoV-2 Evolutionary Dynamics by Pharmaceutical Factors.Infectious diseases & immunity · 2024Review
- Investigating the influencing factors of vaccination decisions for newly developed and established vaccines: a comparative study based on latent class logit models in China.Frontiers in public health · 2024Article
- Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates.MedComm · 2023Article
- Article
- Vaccination strategies, the power of the unmatched double hits.Future science OA · 2023Article
- Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review.Infectious diseases and therapy · 2023Review
- Article
- Spike- and nucleocapsid-based gold colloid assay toward the development of an adhesive bandage for rapid SARS-CoV-2 immune response detection and screening.Microsystems & nanoengineering · 2023Article
- A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?Medicine · 2022Article
- CalScope: Monitoring Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence From Vaccination and Prior Infection in Adults and Children in California May 2021-July 2021.Open forum infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) vaccines have very successfully decreased the disease risk as we know; some key information remains unknown due to the short development history and the lack of long-term follow-up studies in vaccinated populations. One of the unanswered issues is the protection duration conferred after COVID-19 vaccination, which appears to play a pivotal role in the future impact of pathogens and is critical to inform the public health response and policy decisions. Here, we review current information on the long-term effectiveness of different COVID-19 vaccines, persistence of immunogenicity, and gaps in knowledge. Meanwhile, we also discuss the influencing factors and future study prospects on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.